Enhanced Control of Bladder-Associated Tumors Using Shrimp Anti-Lipopolysaccharide Factor (SALF) Antimicrobial Peptide as a Cancer Vaccine Adjuvant in Mice

文化大學機構典藏 CCUR > 理工學院 > 理學院 > 生命科學系 > 期刊論文 > Item 987654321/30607

Please use this identifier to cite or link to this item: https://irlib.pccu.edu.tw/handle/987654321/30607

Title:	Enhanced Control of Bladder-Associated Tumors Using Shrimp Anti-Lipopolysaccharide Factor (SALF) Antimicrobial Peptide as a Cancer Vaccine Adjuvant in Mice
Authors:	Huang, Han-Ning Rajanbabu, Venugopal Pan, Chieh-Yu Chan, Yi-Lin Chen, Jyh-Yih Wu, Chang-Jer
Contributors:	Dept Life Sci
Keywords:	SALF antimicrobial peptide MBT-2 bladder tumor cancer vaccine bladder tumor
Date:	2015-05
Issue Date:	2015-10-23 14:08:44 (UTC+8)
Abstract:	Shrimp anti-lipopolysaccharide factor (SALF) is an antimicrobial peptide with reported anticancer activities, such as suppression of tumor progression. In this study, we prepared a potential cancer vaccine comprised of SALF in conjunction with the cell lysate of inactivated murine bladder carcinoma cells (MBT-2), and evaluated its efficacy in a mouse tumor model. Our study shows that SALF added to cell culture media inhibits growth progression of MBT-2, and that SALF together with inactivated MBT-2 lysate elevates the level of inflammasome activity, and modulates the levels of IL-1, MCP-1, IL-6, IL-12, and TNF- in mouse macrophages. Immunization of 7, 14, and 21 day-old mice with the vaccine prevented growth of MBT-2 cell-mediated tumors. The vaccine was found to enhance expression of T-cell, cytotoxic T cells, and NK cells in the immunized mice groups. Recruitment of macrophages, T-helper cells, and NK cells was enhanced, but levels of VEGF were decreased in immunized mice. This report provides empirical evidence that our SALF as vaccine adjuvant enhances antitumor immunity in mice.
Relation:	MARINE DRUGS 卷: 13 期: 5 頁碼: 3241-3258
Appears in Collections:	[生命科學系] 期刊論文

Files in This Item:

File	Description	Size	Format
index.html		0Kb	HTML	381	View/Open

View Licence

Loading...